A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
List view / Grid view
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
The role that retrons in bacteria has been discovered by researchers, who found they protect colonies when infected by viruses.
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
Researchers have found that, in rainbow trout models, phages on mucosal surfaces infect pathogenic bacteria, providing protection.
Researchers have discovered that patients with alcoholic hepatitis had high numbers of a destructive gut bacterium and they were able to use a cocktail of phages to target and kill the bacteria, eradicating the disease.
Researchers have found a specific strain of Helicobacter pylori strongly correlated with stomach cancer...
Researchers have genetically engineered bacteria as a potential new treatment for constipation, the finding is significant in part because there are few approved constipation remedies on the market...
Brazilian scientists show that parasite's penetration of host cells increases expression of certain microRNAs capable of inhibiting the action of the immune system...
27 May 2016 | By Victoria White, Digital Content Producer
Professor Martha Clokie has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world...
22 February 2016 | By Katie Sadler
Pherecydes Pharma has announced the appointment of Guy-Charles Fanneau de La Horie, MBA as its new Chief Executive Officer.